Study of ARQ 197 Monotherapy

Summary

A phase II open-label study with ARQ 197 administered orally and twice daily as monotherapy in patients with previously treated advanced/recurrent gastric cancer. The primary endpoint is disease control and the secondary efficacy endpoints include antitumor effect (tumor response), progression-free survival and overall survival. The pharmacokinetic profile and the safety profile are also evaluated.

Timeline

Start

2010-06

Primary completion

2011-08

Completion

2011-08

Drugs

Indications